Abstract:To retrospectively analyze the effect of postoperative intensity-modulated radiation therapy (IMRT) on the recurrence and survival in patients with lymph node positive or Stage III thoracic esophageal squamous cell carcinoma (TESCC), and evaluate the role of postoperative IMRT in the TESCC therapy. From January 2004 to June 2009, 535 patients with TESCC underwent radical resection with or without postoperative IMRT were eligible for analysis. Inclusion criteria: (1) having undergone radical resection (R0); (2) a diagnosis of squamous cell carcinoma confirmed by pathological studies; (3) Karnofsky performance status scale ≥70; (4) Preoperative neoadjuvant therapy was not proceeded; (5) postoperative pathologic stage was IIb or III. According to UICC02 stage classification, 122 patients were stage IIb and 413 patients were stage III. Patients were grouped to surgery alone (n = 345) and surgery plus postoperative IMRT (n = 190). The median total dose in postoperative IMRT was 60 Gy. The Kaplan-Meier method was used to calculate the survival rates, and the log-rank test was used for univariate analysis. The chi-square test was used to analyze the sites of failure of esophageal cancer with different treatments. The 1-, 3-, and 5-year overall survival (OS) and disease-free survival (DFS) for all the patients were 79.5%, 42.7%, 32.8%, and 67.2%, 38.0%, 32.5%, and the median OS and DFS were 28.6 months and 21.5 months, respectively. For patients with stage IIb and stage III, the 5-year OS rates were 45.3% and 29.2%, respectively (p = 0.001). The 5-year OS in the patients with lymph node positivity was 28.5% in the group receiving surgery alone and 38.9% in the group undergoing surgery plus postoperative IMRT (p = 0.000). The 5-year OS rates in patients with stage III was 24.3% in the surgery group and 38.0% in the surgery plus postoperative IMRT group, respectively (p = 0.001). Use of postoperative IMRT resulted in significant decrease in intrathoracic recurrence from 33.6% to 13.3% (p = 0.000) as well as supraclavicular recurrence from 13.4% to 6.1% (p = 0.012), Similarly, use of postoperative IMRT obviously delayed the median local recurrence from 10.7 months to 20.7 months and the median system metastases from 8.8 months to 14.5 months. While systemic metastases increased from 21.6% to 30.4% (p = 0.032) by postoperative IMRT treatment. Postoperative IMRT reduced local recurrence and improved survival for patients with lymph node positive or stage III TESCC, which would provide rationale in establishing patient selection criteria for the postoperative IMRT for TESCC after surgery.

Safety and Efficacy of Computed Tomography–Guided Iodine-125 Brachytherapy As a Salvage Treatment for Locoregional Lymph Node Recurrence of Esophageal Cancer

CT-guided 125I brachytherapy for mediastinal metastatic lymph nodes recurrence from esophageal carcinoma: effectiveness and safety in 16 patients.

Interstitial 125I Brachytherapy As a Salvage Treatment for Refractory Cervical Lymph Node Metastasis of Thoracic Esophageal Squamous Cell Carcinoma after External Irradiation with a CT-Guided Coplanar Template-Assisted Technique: A Retrospective Study.

Efficacy and Toxicity of Iodine-125 Seed Implantation for Lymph Node Recurrence Secondary to Esophageal Cancer after Radiotherapy: a Multicenter Retrospective Study

CT-guided iodine-125 brachytherapy is an effective palliative treatment for the right lower paratracheal lymph nodes metastasis previously treatment failure

The effectiveness and prognostic factors of radioactive iodine-125 seed implantation for the treatment of cervical lymph node recurrence of esophageal squamous cell carcinoma after external beam radiation therapy

Computed Tomography Fluoroscopy-Guided Percutaneous 125I Seed Implantation for Safe, Effective and Real-Time Monitoring Radiotherapy of Inoperable Stage T1-3N0M0 Non-Small-cell Lung Cancer.

Postoperative Intensity Modulated Radiation Therapy Improved Survival of Lymph Node-Positive or Stage III Squamous Cell Carcinoma Esophagus

[Ct-Guidance Interstitial Iodine-125 Seed Brachytherapy As a Salvage Therapy for Recurrent Head and Neck Carcinoma].

125I Brachytherapy of Locally Advanced Non-Small-cell Lung Cancer after One Cycle of First-Line Chemotherapy: a Comparison with Best Supportive Care.

Long-Term Outcomes and Prognostic Analysis of Computed Tomography-Guided Radioactive 125I Seed Implantation for Locally Recurrent Rectal Cancer After External Beam Radiotherapy or Surgery

Salvage radiotherapy for locoregional recurrence of esophageal cancer after surgery

CT-guided Permanent 125I Seed Interstitial Brachytherapy for Recurrent Retroperitoneal Lymph Node Metastases after External Beam Radiotherapy

Brachytherapy by Percutaneous Paracentesis Implantation of Iodine-125 Seeds for Lung Cancer

Interstitial 125I Seed Implantation for Cervical Lymph Node Recurrence after Multimodal Treatment of Thoracic Esophageal Squamous Cell Carcinoma.

Efficacy and Safety of CT-Guided 125I Seed Implantation As a Salvage Treatment for Locally Recurrent Head and Neck Soft Tissue Sarcoma after Surgery and External Beam Radiotherapy: A 12-Year Study at a Single Institution

Salvage Concurrent Radio-chemotherapy for Postoperative Local Recurrence of Squamous Cell Esophageal Cancer

Efficacy of Intracavitary Brachytherapy for Recurrent Esophageal Cancer after Radiotherapy

Interstitial I-125 Seed Implantation For Cervical Lymph Node Recurrence After Multimodal Treatment Of Thoracic Esophageal Squamous Cell Carcinoma

Efficacy and Prognosis of CT-guided of 125I Radioactive Seeds Implantation Brachytherapy As Salvage Treatment for Recurrent Nasopharyngeal Carcinoma after External Beam Radiotherapy--a Long-Term Experience at a Single Institution

Salvage chemoradiation therapy for recurrence after radical surgery or palliative surgery in esophageal cancer patients: a prospective, multicenter clinical trial protocol